Hyperacute bacterial conjunctivitis is a severe, sight threatening ocular infection that warrants immediate ophthalmic work-up and management. Bacterial conjunctivitis requires treatment with antibiotics for 5-7 days that may result in poor patient compliance with conventional dosage forms due to greater frequency of drug administration, that is, 2-3 drops every 2-3 h.\[[@ref1]\] This is because in ocular delivery, the physiological constraints imposed by the protective mechanisms of the eye lead to low absorption of drugs, resulting in short duration of the therapeutic effect. When a drug solution is dropped into the eye, the effective tear drainage and blinking action of the eye result in a 10-fold reduction in the drug concentration within 4-20 min.\[[@ref1]\] The availability of medicament at corneal surface would be significantly improved if the precorneal residence time of drugs could be increased. Several new preparations such as inserts,\[[@ref2]\] collagen shields,\[[@ref3]\] and colloidal systems, such as liposomes,\[[@ref4][@ref5]\] nanoparticles,\[[@ref6][@ref7]\] and nanocapsules\[[@ref8][@ref9]\] have been developed for ophthalmic use, not only to prolong the ocular contact time of the vehicle but also to slow down drug elimination.\[[@ref10]\] The use of nanotechnology-based drug delivery systems like microemulsions, nanosuspensions, nanoparticles, solid lipid nanoparticles, niosomes, dendrimers, and liposomes has led to the solution of various solubility-related problems of poorly soluble drugs, like dexamethasone, budesonide, ganciclovir, and so on.\[[@ref11]\] However, these novel preparations have some disadvantages, such as poor compliance. Out of these novel formulations; *in situ* gel and nanoparticles have been established as the promising one. In our previous work, we found that these formulations have their own disadvantages. For example, *in situ* gel remains for 12-15 h,\[[@ref12]\] whereas poly lactic co glycolic acid (PLGA) nanoparticles are nonmucoadhesive, so are drained out of eyes quickly.\[[@ref13]\] In our present work, we try to combine both these formulation strategies as a nanoparticles suspended in liquid dosage form suitable to be administered by instillation into the eye which, upon exposure to physiological conditions, changes to the gel phase, thus increasing the precorneal residence time of the nanoparticles and enhancing ocular bioavailability. Our group has coined the term "nanoparticle laden *in situ* gel" for this formulation.\[[@ref14]\]

In our study, we used third generation flouroquinolone sparfloxacin for formulation evaluation. Hence, in the present work we develop and evaluate new system, that is, sparfloxacin PLGA nanoparticle laden *in situ* gel for ophthalmic delivery to improve precorneal residence time and thus ocular bioavailability.

Materials and Methods {#sec1-1}
=====================

Materials {#sec2-1}
---------

Sparfloxacin was received as kind gift from Micro Labs Ltd. (Chandigarh, India); PLGA (50:50), intravenous = 0.2 dL/g, was obtained from Purac Biomaterial, Singapore), polyvinyl alcohol (PVA, MW 95,000) was obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Chitosan (practical grade, 75%-85% deacetylated, and molecular weight 150 kDa) was obtained as kind gift from M/s India Sea Foods, India. All other chemicals were of analytical grade.

Preparation of nanoparticle laden *in situ* gel {#sec2-2}
-----------------------------------------------

Nanoparticles were prepared as per our previous published work.\[[@ref13]\] Briefly, nanoprecipitation technique was applied to prepare sparfloxacin nanoparticles. Drug and polymer in ratio of 1:10 (keeping drug 10 mg and PLGA 100 mg) were dissolved in acetone (5 mL) at room temperature. The resulted solution was slowly dropped with speed manually (approx. 0.5 mL/min) into water (20 mL) containing PVA (1.5% w/v) with continuous magnetic stirring at 1800 rpm. Acetone and some water were evaporated, and the final volume of the aqueous suspension was collected. The nanosuspension was then centrifuged at 18,000 rpm, 20°C for 1 h (Remi, India). Nanoparticles were collected and washed (3 times) with distilled water using previously described centrifugation approach and then lyophilized by means of Christ Alpha 1-4 lyophilizator (Christ, Germany) using 1% w/v mannitol as lyoprotectant. Whereas, *in situ* gel base is prepared by dissolving 0.5% w/v chitosan in 1% v/v acetic acid, pH adjusted to 5.5-6.0 with buffer saline.\[[@ref12]\]

Weighed quantity of drug-loaded freeze-dried nanoparticles (equivalent to the prescribed dose of sparfloxacin 0.3% w/v) were taken and dispersed in the respective 1 ml of placebo *in situ* gel base (0.5%w/v chitosan solution) to form nanoparticle laden *in situ* gel. Freeze-dried nanoparticles were weighed accurately on the basis of its drug loading and release pattern \[[Table 1](#T1){ref-type="table"}\].\[[@ref13]\]

###### 

Final composition of sparfloxacin nanoparticles laden *in situ* gel
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Physicochemical characterization {#sec2-3}
--------------------------------

Physicochemical characterization of the developed nanoparticles laden *in situ* gel were carried out and compiled in [Table 2](#T2){ref-type="table"}.

###### 

Physicochemical characterization of nanoparticles laden *in situ* gel
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Clarity {#sec2-4}
-------

The clarity of the formulations after and before gelling was determined by visual examination of the formulations under light alternatively against white and black backgrounds.

Gelation pH {#sec2-5}
-----------

Gelation pH is the pH at which the solution form of the formulation was changed to gel. Formulation was taken in a beaker and 1M NaOH was added dropwise with continuous stirring. pH was checked using pH meter. The pH at which sudden change in viscosity was observed and noted is recorded as gelation pH.

Viscosity {#sec2-6}
---------

Viscosity of formulations were determined by using Brookfield\'s viscometer (model DV II, spindle no. 02, at 20 rpm), on formulation pH (6.0) and gelation pH near 7.0.

*In vivo* ocular retention study-Gamma scintigraphy {#sec2-7}
---------------------------------------------------

Gamma scintigraphy is used to assess *in vivo* precorneal drainage of the developed formulation. Male New Zealand albino rabbits of either sex weighing 1.8-2.5 kg and free of any signs of ocular inflammation or gross abnormality were used in the study. Animals were procured from the animal house of Institute of Nuclear Medicine and Allied Sciences Delhi, India and all study protocols were approved by local institutional animal ethics committee. Sparfloxacin was radiolabeled with Tc-99m by direct labeling method using stannous chloride as reducing agent as per previous reported method.\[[@ref13]\] Gamma camera (Millenium VG, USA), autotuned to detect the 140 KeV radiation of Tc~99m~ was used for scintigraphy study. Rabbits were anesthetized using ketamine HCl injection given intramuscularly in a dose of 15 mg/kg body weight. The rabbits were positioned 5 cm in front of the probe and 50 μL of the radiolabeled formulation was instilled onto the left corneal surface of the rabbits. Recording was started 5 s after instillation and continued for 30 min using 128 × 128 pixel matrix. Individual 60 frames (60 × 30 s) were captured by dynamic imaging process. Region of interest was selected on one frame of the image and time-activity curve was plotted to calculate the rate of drainage from eye. A single whole body static image was also taken after 6 h of instillation of drug/formulation. Each formulation was tested on three rabbits.

Results and Discussion {#sec1-2}
======================

*In situ* gel and nanoparticles have their own merits and demerits. *In situ* gel stays only for 12 h, whereas PLGA and conjunctiva is anionic in nature and hence PLGA nanoparticles are not able to be retained for the longer time. To increase the duration, we entrapped PLGA nanoparticles in cationic chitosan *in situ* gel system. Chitosan is a cationic polymer and hence will make link with both PLGA nanoparticles and conjunctiva and thus increases retention. As chitosan act both as pH sensitive and permeation enhancer, the viscosity of the chitosan increases when it reaches to eye pH at 7.4. This combination will allow nanoparticles to stay for longer duration and provide optimum drug release. To achieve most out of these two delivery systems, we have combined both the system to develop "nanoparticles laden *in situ* gel." The nanoparticle size was near 180 nm in concordant with our previously reported results.\[[@ref13]\] The quantity of nanoparticles was calculated on the basis of drug loading and release, we have taken 40 mg of SN to prepare 1 ml of respective nanoparticles laden *in situ* gel (SNG). Final composition of SNG is given in [Table 1](#T1){ref-type="table"}. The developed nanoparticles laden *in situ* gels were then evaluated for various physicochemical characteristics as given in [Table 2](#T2){ref-type="table"}. The preparation is well-dispersed with slight turbidity. After mixing, no difference is found in gelation pH and viscosity of the formulation.

Gamma scintigraphy {#sec2-8}
------------------

Pharmacoscintigraphy is a tool to analyze the retention time of the formulation in cul-de-sac. For gamma scintigraphic studies, sparfloxacin was labeled with radionuclide Tc-99m using stannous chloride as reducing agent. Tc-99m was chosen for the purpose because of its moderate half life (6 h). Further it emits gamma rays, which have relatively low energy as compared to α and β rays, so leads to no serious health hazards to the workers. Sparfloxacin was instantaneously labelled with Tc-99m. Labelling efficiency was checked by instant thin layer chromatography (ITLC) using 100% acetone as mobile phase. The Rf value of free Tc is \~0.9, so it reaches to the top of the ITLC strip while the complexed Tc (drug-Tc complex) cannot travel much due to difference in molecular weight and is retained at the base of ITLC strip. Thus, from the difference in the top and bottom counts, labelling efficiency was calculated. After prelabeling efficiency studies which include labelling parameters like stannous chloride concentration and pH were optimized and a 50 μg stannous chloride concentration at pH 7.0 was found to give the maximum labelling efficiency (95.2%). In these conditions, minimum colloids (1%) were produced. The observation of the acquired gamma camera images showed a good spreading over the entire precorneal area for developed ocular formulations of sparfloxacin \[*in situ* gel (SG), nanosuspension (SN), nanoparticle laden *in situ* gel (SNG)\], immediately after administration as compared to marketed formulation. Marketed formulation cleared very rapidly from the corneal region and reached in to systemic circulation via nasolacrimal drainage system as significant activity was recorded in kidney and bladder after 6 h of ocular administration \[[Figure 1a](#F1){ref-type="fig"}\], whereas formulations SG, SN, and SNG were retained for longer duration at corneal surface. No significant radioactivity was observed in kidney and bladder after 6 h of administration of these formulations \[Figure [1b](#F1){ref-type="fig"}-[d](#F1){ref-type="fig"}\]. To differentiate between these formulations, the curves of the % radioactivity remained on the corneal surface as a function of time (30 min dynamic imaging) was also plotted \[[Figure 2](#F2){ref-type="fig"}\]. The retention on cornea follows the following sequence:

![Static images of rabbit after 6 h of administering sparfloxacin formulations (a) marketed, (b) *in situ* gel, (c) nanosuspension, and (d) nanoparticles laden *in situ* gel](JPBS-5-162-g003){#F1}

![Gamma scintigraphy dynamic study](JPBS-5-162-g004){#F2}

Marketed formulation \< nanosuspension \< *in situ* gel \< nanoparticle laden *in situ* gel {#sec2-9}
-------------------------------------------------------------------------------------------

It shows that the nanoparticles laden *in situ* gel retained for the longer duration in the eye giving extended release than nanosuspension and *in situ* gel alone, whereas the marketed formulation drained out of the eye with in 30 min. Due to mucoadhesive property of chitosan, *in situ* gel-based formulation cleared at slowest rate as compare to nanosuspension and retained at corneal surface for longest time duration. Further, the viscosity of chitosan is raised due to change in physiological conditions of pH (\>7) and ionic concentration of the formulation upon instillation in to eye as a result of buffering action of the tear fluid. Chitosan also acts as penetration enhancer that increases the transport of drug across cornea.

Conclusion {#sec1-3}
==========

Our previous study shows that the PLGA nanoparticles, due to smaller size, are able to provide prolong retention on the eye than the marketed formulation. PLGA is an anionic polymer and hence it is nonmucoadhesive in nature. To enhance the efficacy of the nanoparticulate formulation, we incorporate them in cationic chitosan *in situ* gel to make nanoparticle laden *in situ* gel, which helps in retention of nanoparticles on the eye. A good spreading and retention of formulation was observed in gamma scintigraphy studies as compared to marketed formulation. In time activity curve, there is a minimal falls in counts/s of formulation as compared to rapid fall of marketed formulation further shows that the nanoparticles laden *in situ* gel stay for longer time on the eye.
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